Non-Invasive Risk Assessment with Machine Intelligence

Country
India
Sustainable development goals
  • Gender equality
  • Good health and well-being
  • Industry innovation and infrastructure
Project link
https://www.niramai.com/

About the project

Niramai is a start-up that has developed the Thermalytix software which can detect early-stage breast cancer in a non-contact and non-invasive assessment using high-resolution thermal images.

More project information

Niramai is a start-up that has developed the Thermalytix software which can detect early-stage breast cancer in a non-contact and non-invasive assessment using high-resolution thermal images. Breast cancer is the leading cause of cancer deaths in women today. According to World Health Organization, one in every 12 women have the risk of a breast abnormality. Indian women have only about 50% chance of survival. Survival rates in developing countries like India are very low due to accessibility and affordability issues of screening tests such as mammography. In addition, Mammography is not very effective in younger women with dense breasts. This leaves a gap in current screening methods that Niramai seeks to fill. Thermalytic is an artificial intelligence-enabled computer-aided diagnosis solution that automates interpretation of high-resolution thermal images and identifies potential malignant lesions. The solution offered by Niramai is a low cost, easy to use, portable and is effective in all age groups. The core of NIRAMAI software consists of novel computer algorithms based on artificial intelligence and machine learning that analyze thermal images and generate quantitative interpretation. Niramai uses FDA 510(k) cleared FLIR A and E series thermal cameras and Thermalytix to generate a so-called Thermal Analysis report and interpretation result automatically, that radiologist can review before making a final observation on the patient.

Thermalytic was found to have better sensitivity than bother Mammography and Clinical Breast Examination for breast cancer screening in the first tests conducted by NIRAMAI published in Engineering and Technology International Journal of Medical and Health Science. The test was conducted with data from a total of 147 patients, Thermalytix showed 98% sensitivity and specificity. Niramai’s solution is a low cost, accurate, automated, portable cancer screening tool that can be operated by a simple clinician. Unlike mammography, Thermalytix’s imaging method is radiation free, non-touch, not painful and works for women of all ages. The non-invasive component of the product is a crucial feature that allows women to feel more comfortable with such procedures and not compromise on their health because of it. Today, Thermalytix has been tested on more than 4000 women in 12 hospitals/diagnostic center as well as screening camps. 3 clinical trials, comparing Thermalytix with current standard of care, have been published in peer reviewed conference/journals. The results from these clinical trials indicate very high accuracy of Thermalytix that is comparable and sometimes better that Mammography.      

Niramai’s portable solution can be deployed not only at hospitals and diagnostic centres but rural camps as well where there is a shortage of skilled medical professionals. The company conducts and supports screening camps for the rural and urban poor in collaboration with organizations such as Karnataka Cancer Society, outreach arms of various reputed hospitals and health-focused NGOs. In addition, they are reportedly planning to set up a mobile screening van to enable visits in rural areas along with the equipment and enable more women to be screened for early-stage breast cancer. By innovating on cancer detection technology, Niramai contributes to the SDG 3 (Good Health and Well-Being) and SDG 9 (Industry, Innovation and Infrastructure); the non-intrusive technology